Edaravone/Dexborneol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Edaravone/Dexborneol Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Edaravone/Dexborneol can convert its Small molecule drug profile and CPT1A x PRDX1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Edaravone/Dexborneol (query alias: Edaravone/Dexborneol) |
|---|---|
| Modality / target | Small molecule drug; CPT1A x PRDX1; CPT1A agonists, PRDX1 agonists, Neuroprotectants |
| Highest global status | Approved |
| Originator | Simcere Pharmaceutical Group Ltd. |
| Active developers | Neurodawn Pharmaceutical Co., Ltd., Simcere Pharmaceutical Co., Ltd., Pharmaceutical Biotechnology Qidong Co. Ltd. |
The MCP disease footprint includes Acute Ischemic Stroke, Brain Infarction, Blood brain barrier defect. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600117649 | Phase 4 | Not yet recruiting | 37 | Postoperative pulmonary complications |
| ChiCTR2600125711 | Phase 2 | Not yet recruiting | 53 | Proportion of patients achieving a >=25% reduction in brain edema volume on FLAIR-MRI at 3 months after treatment |
| ChiCTR2600119095 | Not Applicable | Pending | 79 | Change in MoCA score from baseline at 6 months |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Exploratory Post Hoc Analysis of Neutrophil-to-Lymphocyte Ratio as a Novel Response Biomarker for Edaravone Oral Suspension-Treated Patients With ALS
Phase 3; n=442; evaluation: Positive. Reported fields: NLR(48 weeks): P-Value = 0.065; P-Value = 0.038; NLR(48 weeks): P-Value = 0.065; P-Value = 0.038; NLR(48 weeks): P-Value = 0.065; P-Value = 0.038
Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis
Phase 3; n=243; evaluation: Positive. Reported fields: ALSFRS-R = 35.1 point
Analysis of Long‐Term Function and Survival of Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis Using <scp>PRO</scp>‐<scp>ACT</scp> Data as Historical Placebo Controls
Not Applicable; n=420; evaluation: Positive. Reported fields: survival benefit = 78 edaravone oral suspension-treated patients from Studies MT-1186-A02/A04 demonstrated a survival benefit versus 78 matched PRO-ACT placebo patients (p = 0.005) ; survival benefit = 78 edaravone oral suspension-treated patients from Studies MT-1186-A02/A04 demonstrated a survival benefit versus 78 matched PRO-ACT placebo patients (p = 0.005)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Edaravone/Dexborneol addresses Acute Ischemic Stroke, Brain Infarction, Blood brain barrier defect. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-12-22 | Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) | Approved | US$2,500.0M stated total |
| 2024-07-12 | 华东医药股份有限公司关于全资子公司与澳宗生物签署产品独家许可协议的公 告 | Phase 3 | US$13.8M upfront; US$163.2M milestones |
| 2023-08-27 | Specialised Therapeutics acquires commercialisation rights to new oral MND therapy | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
